Search Taltz (type in keywords)
Search Medical Information
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Taltz ® (ixekizumab) injection
80 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
VIDEO: TALTZ® (ixekizumab): Phase 3 Trial In Pediatric Patients With Plaque Psoriasis
Significantly more pediatric patients treated with ixekizumab vs placebo achieved PASI 75 and sPGA (0,1) as early as Week 4 in IXORA-PEDS. The safety profile was generally consistent with that seen in adults with moderate-to-severe plaque psoriasis.
Date of Last Review: May 05, 2023
Document Number: VV-MED-92939
Are you satisfied with this content?